Search
Bifeprunox
go.drugbank.com/drugs/DB04888InvestigationalBifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBepotastine
go.drugbank.com/drugs/DB04890ApprovedBepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. … The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.
Categories: Heterocyclic Compounds, 1-RingProducts: DOLCETTINA®Clevidipine
go.drugbank.com/drugs/DB04920ApprovedInvestigationalClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersIndacaterol
go.drugbank.com/drugs/DB05039ApprovedInvestigationalIndacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. … Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease.
Mixtures: ATECTURA®BREEZHALER®150/80 MCG POLVO PARA INHALACIÓN CÁPSULA DURA, ULTIBRO- BREEZHALER®Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesOdevixibat
go.drugbank.com/drugs/DB16261ApprovedInvestigational[L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid]. … Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 2-RingOrelabrutinib
go.drugbank.com/drugs/DB16272InvestigationalOrelabrutinib is under investigation in clinical trial NCT04305197 (A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)).
Categories: Heterocyclic Compounds, 1-RingSynonyms: 奥布替尼Veliflapon
go.drugbank.com/drugs/DB16346InvestigationalVeliflapon is under investigation in clinical trial NCT00353067 (Veliflapon (Dg-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina).
Categories: Heterocyclic Compounds, 2-RingBexotegrast
go.drugbank.com/drugs/DB16515InvestigationalPLN-74809 is a small-molecule that dually inhibits both α<sub>v</sub>β<sub>6</sub> and α<sub>v</sub>β<sub>1</sub> to treat both idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC … The compound was granted orphan drug designation by the US FDA in August 2018 for treatment of IPF, and Pliant Therapeutics recently raised $100 million in Series C financing to support further clinical
Synonyms: (2S)-4-(2-METHOXYETHYL-(4-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)BUTYL)AMINO)-2-(QUINAZOLIN-4-YLAMINO)BUTANOIC ACID, (S)-4-[(2-Methoxyethyl)[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl]amino]-2-[(quinazolin-4-yl)amino]butanoic acidDeucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigationalDeucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesProducts: SOTYKTU 6 mg film coated tablets, SOTYKTU® 6MG TABLETAS RECUBIERTASVecabrutinib
go.drugbank.com/drugs/DB16657InvestigationalVecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers).
Categories: Heterocyclic Compounds, 1-Ring